A Study to Evaluate the Efficacy of an RSV F Vaccine in Older Adults
Phase of Trial: Phase III
Latest Information Update: 05 Jun 2017
At a glance
- Drugs RSV F protein vaccine-Novavax (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms Resolve
- Sponsors Novavax
- 10 Jan 2017 Status changed from active, no longer recruiting to completed.
- 15 Sep 2016 Primary endpoint has not been met. (Numbers and percentages of subjects with moderate-severe RSV-LRTD), according to a Novavax Inc. media release.
- 15 Sep 2016 Results published in the Novavax Inc. Media Release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History